OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE) February 27, 2018 –Shionogi & Co., Ltd. (hereafter "Shionogi") announced today that the New Drug Application (NDA) for lusutrombopag (S-888711), an investigational, once-daily, orally…Original Article
Shionogi Announces FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) Acceptances for Lusutrombopag (S-888711)
